KRAS and colorectal cancer: Evidence coming from other in vitro and in vivo studies demonstrated efficient induction of apoptosis in KRAS or BRAF mutant colorectal cancer cell lines treated with navitoclax in combination with the TORC1/2 inhibitor AZD8055 but not in the wild-type controls.